The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis

Radiotherapy and Oncology

Volumn 50, Issue 1, 1999, Pages 13-23

  Begga, Adrian C ^a   Haustermans, Karin ^a   Hart, August A M ^a   Dische, Stan ^b   Saunders, Michele ^b   Zackrisson, Bjorn ^c   Gustaffson, Hans ^c   Coucke, Philippe ^d   Paschoud, Nicolas ^d   Hoyer, Morten ^e   Overgaard, Jens ^e   Antognoni, Paolo ^f   Richetti, Antonella ^f   Bourhis, Jean ^g   Bartelink, Harry ^a   Horiot, Jean Claude ^h   Corvo, Renzo ⁱ   Giaretti, Walter ⁱ   Awwad, Hassan ^j   Shouman, Tarek ^j   Jouffroy, Thomas ^k   Maciorowski, Zofia ^k   Dobrowsky, Werner ^l   Struikmans, Henk ^m   Rutgers, Derk ^m   Wilson, George D ⁿ   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c UMEÅ UNIVERSITY   (Sweden)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^f OSPEDALE DI CIRCOLO   (Italy)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h Ctre de Lutte Contre le C G F L   (France)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j NATIONAL CANCER INSTITUTE   (Egypt)

^k INSTITUT CURIE   (France)

^l MEDICAL UNIVERSITY OF VIENNA   (Austria)

^m AZU   (Netherlands)

ⁿ MOUNT VERNON HOSPITAL   (United Kingdom)

more..

Author keywords

Cell kinetic parameters; DNA synthesis time; Head and neck cancer; Potential doubling time

Indexed keywords

BROXURIDINE; IDOXURIDINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR BIOPSY;

ANALYSIS OF VARIANCE; ANTIMETABOLITES; BROMODEOXYURIDINE; CELL CYCLE; CELL DIVISION; DNA; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; FORECASTING; HEAD AND NECK NEOPLASMS; HUMANS; IDOXURIDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033048862     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(98)00147-9     Document Type: Article

References (54)

1. Amdur RJ, Parsons JT, Mendenhall WM, Million RR, Cassisi NJ. Split-course versus continuous-course irradiation in the postoperative setting for squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 1989; 17: 279-285.
2. Antognoni P, Bignardi M, Cazzaniga LF, et al. Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kinetics - A phase II multicenter study. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 1137-1145.
3. Awwad HK, KhafagY Y, Barsoum M, et al. Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: Influence of tumour proliferation. Radiother. Oncol. 1992; 25: 261-266.
4. Barton MB, Keane TJ, Gadalla T, Maki E. The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal. Radiother. Oncol. 1992; 23: 137-143.
5. Begg AC, Hofland I, Moonen L, et al. The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: An interim report. Int. J. Radiat. Oncol. Biol. Phys. 1990; 19: 1449-1453.
6. Begg AC, Hofland I, van Glabbeke M, Horiot JC. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: Results from the EORTC cooperative trial 22851. Semin. Rad. Oncol. 1992; 1: 22-25.
7. Begg AC, McNally NJ, Shrieve DC, Karcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985; 6: 620-626.
8. Begg AC, Moonen L, Hofland I, Dessing M, Bartelink H. Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: Intratumour sampling variations. Radiother. Oncol. 1988; 11: 337-347.
9. Bennett MH, Wilson GD, Dische S, et al. Tumour proliferation assessed by combined histological and flow cytometric analysis: Implications for therapy in squamous cell carcinoma in the head and neck. Br. J. Cancer 1992; 65: 870-878.
10. Bentzen SM, Thames HD. Clinical evidence for tumor clonogen regeneration: Interpretations of the data. Radiother. Oncol. 1991; 22: 161-166.
11. Bourhis J, Dendale R, Hill C, et al. Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 Gy in 7 weeks. Int. J. Radiat. Oncol. Biol. Phys. 1996; 35: 471- 476.
12. Bourhis J, Wilson G, Wibault P, et al. In vivo measurement of the potential doubling time by flow cytometry in oropharyngeal cancer treated by conventional radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1993; 26: 793-799.
13. Corvo R, Giaretti W, Sanguineti G, et al. Potential doubling time in head and neck tumors treated by primary radiotherapy: Preliminary evidence for a prognostic significance in local control. Int. J. Radiat. Oncol. Biol. Phys. 1993; 27: 1165-1172.
14. Corvo R, Giaretti W, Sanguineti G, et al. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J. Clin. Oncol. 1995; 13: 1843-1850.
15. Dean PN, Dolbeare F, Gratzner H, Rice GC, Gray JW. Cell-cycle analysis using a monoclonal antibody to BrdUrd. Cell Tissue Kinet. 1984; 17: 427-436.
16. Dolbeare F, Gratzner H, Pallavicini MG, Gray JW. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc. Natl. Acad. Sci. USA 1983; 80: 5573-5577.
17. Dubben HH. No clinical evidence for the influence of overall treatment time on TCD50 of head and neck tumours. Radiother. Oncol. 1992; 25: 142-143.
18. Eschwege F, Bourhis J, Girinski T, et al. Predictive assays of radiation response in patients with head and neck squamous cell carcinoma: A review of the Institute Gustave Roussy experience. Int. J. Radiat. Oncol. Biol. Phys. 1997; 39: 849-853.
19. Fowler JF. Rapid repopulation in radiotherapy: A debate on mechanism. The phantom of tumor treatment-continually rapid proliferation unmasked. Radiother. Oncol. 1991;22:156-158.
20. Fowler JF, Chappell R. Local control versus dose or overall time: From coefficients to percentages. Br. J. Radiol. 1994; 67: 1108-1112.
21. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1992; 23: 457-4-67.
22. Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother. Oncol. 1992; 25: 273-279.
23. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 1982; 21: 474-475.
24. Haustermans K, Fowler J, Geboes K, Christiaens MR, Lerut A, Vanderschueren E. Relationship between potential doubling time (T-pot), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: Is it worthwhile to measure T-pot? Radiother. Oncol. 1998; 4: 157-167.
25. Haustermans K, Hofland I, Pottie G, Ramaekers M, Begg AC. Can measurements of potential doubling time (Tpot) be compared between laboratories? A Quality Control Study Cytometry 1995; 19: 154-163.
26. Haustermans K, Hofland I, Ramaekers M, et al. Enrichment of tumor cells for cell kinetic analysis in human tumor biopsies using cytokeratin gating. Radiother. Oncol. 1996; 41: 237-248.
27. Haustermans K, VanuytseL L, Geboes K, et al. In vivo cell kinetic measurements in human oesophageal cancer: What can be learned from multiple biopsies? Eur. J. Cancer 1994; 30A: 1787-1791.
28. Horiot JC, Begg AC, Le Fur R, et al. Present status of EORTC trials of hyperfractionated and accelerated radiotherapy on head and neck carcinoma. Recent Results Cancer Res. 1994; 134: 111-119.
29. Horiot JC, Bontemps P, Vandenbogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother. Oncol. 1997 ; 44: 111-121.
30. Horiot JC, LeFlur R, Schraub S, et al. Status of the experience of the EORTC cooperative group of radiotherapy with hyperfractionated and accelerated radiotherapy. Semin. Rad. Oncol. 1992; 2: 34-37.
31. Hoyer M, Jorgensen K, Bundgaard T, et al. Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. Radiother. Oncol. 1998; 46: 147-155.
32. Knee R, Fields RS, Peters LJ. Concomitant boost radiotherapy for advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 1985; 4: 1-7.
33. Lee WR, Marcus Jr. RB, Sombeck MD, et al. Radiotherapy alone for carcinoma of the vagina: The importance of overall treatment time. Int. J. Radiat. Oncol. Biol. Phys. 1994; 29: 983-988.
34. Lochrin CA, Wilson GD, McNally NJ, Dische S, Saunders MI. Tumor cell kinetics, local tumor control, and accelerated radiotherapy: A preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 1992; 24: 87-91.
35. Maciejewski B, Skladowski K, Pilecki B, et al. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity. Radiother. Oncol. 1996; 40: 137-145.
36. Maciejewski B, Skladowski K, Tarawski R, Zajusz A. Is the 7-day accelerated treatment better than conventional 5-day irradiation of head and neck cancers? In: Kogelnik HD, Sedlmayer F, editors. Progress in Radio-oncology VI, Bologna: Editore, 1998. pp. 753.
37. Overgaard J, Hansen HS, Overgaard M, et al. Importance of overall treatment time of radiotherapy in head and neck carcinoma. Experience from the Danish head and neck cancer study. In: Kogelnik HD, Sedlmayer F, et al., editors. Progress in Radio-oncology VI, Bologna: Monduzzi Editore, 1998. pp. 743.
38. Peters LJ, Ang KK, Thames HD. Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol. 1988; 2: 185-194.
39. Rew DA, Campbell ID, Taylor I, Wilson GD. Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2'-deoxyuridine labelling: A flow cytometric study of 75 tumours. Br. J. Surg. 1992; 7: 335-339.
40. Rew DA, Wilson GD, Taylor I, Weaver PC. Proliferation characteristics of human colorectal carcinomas measured in vivo. Br. J. Surg. 1991; 7: 60-66.
41. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomized multicentre trial. CHART Steering Committee. Lancet 1997; 35: 161-165.
42. Steel GG. Growth Kinetics of Tumours. Oxford: Oxford University Press, 1977.
43. Struikmans H, Rutgers DH, Hordijk GJ, Slootweg PJ, Van der Tweel I, Battermann JJ. Prognostic significance of cell proliferation markers and DNA-ploidy in head and neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 1998; 4: 27-34.
44. Struikmans H, Rutgers DH, Hordijk GJ, Slootweg PJ, Van der Tweel I, Battermann JJ. Interrelationships of DNA-ploidy and cell proliferation markers with T-stage and N-stage in primary laryngeal tumors. Int. J. Radiat. Oncol. Biol. Phys. 1998; 4: 303-308.
45. Taylor JM, Withers HR, Mendenhall WM. Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother. Oncol. 1990; 1: 95-102.
46. Terry NH, Peters LJ. The predictive value of tumor-cell kinetic parameters in radiotherapy: Considerations regarding data production and analysis. J. Clin. Oncol. 1995; 13: 1833-1836.
47. Tsang RW, Fyles AW, Kirkbride P. Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: Correlation between two laboratories and preliminary clinical results. Int. J. Radiat. Oncol. Biol. Phys. 1995; 32: 1319-1329.
48. Wilson GD. Assessment of human tumour proliferation using bromodeoxyuridine - Current status. Acta Oncol. 1991; 3: 903-910.
49. Wilson GD, Dische S, Saunders MI. Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy. Radiother. Oncol. 1995; 36: 189-197.
50. Wilson GD, Paschoud N, Pavy JJ, et al. Reproducibility of measurements of potential doubling time of tumour cells in the multi-centre NCI protocol T92-0045. Br. J. Cancer 1999; 79: 323-332.
51. Wilson MS, West CM, Wilson GD, Roberts SA, James RD, Schofield PF. An assessment of the reliability and reproducibility of measurement of potential doubling times (Tpot) in human colorectal cancers. Br. J. Cancer 1993; 6: 754-759.
52. Wilson MS, West CM, Wilson GD, Roberts SA, James RD, Schofield PF. Intra-tumoral heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer. Br. J. Cancer 1993; 6: 501-506.
53. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988; 2: 131-146.
54. Zackrisson B, Gustafsson H, Stenling R, Flygare P, Wilson GD. Predictive value of potential doubling time in head and neck cancer patients treated by conventional radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1997; 3: 677-683.